Profile data is unavailable for this security.
About the company
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.
- Revenue in USD (TTM)91.06m
- Net income in USD-503.14m
- Incorporated2010
- Employees487.00
- LocationSAGE Therapeutics Inc215 1st StCAMBRIDGE 02142-1213United StatesUSA
- Phone+1 (617) 299-8380
- Fax+1 (617) 299-8379
- Websitehttps://www.sagerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Castle Biosciences Inc | 250.73m | -30.80m | 677.20m | 610.00 | -- | 1.68 | -- | 2.70 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 701.08m | 224.00 | -- | 1.16 | -- | 10,310.04 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 703.65m | 116.00 | -- | 1.89 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| SS Innovations International Inc | 11.22m | -22.75m | 715.40m | 239.00 | -- | 52.85 | -- | 63.76 | -0.1372 | -0.1372 | 0.0698 | 0.0793 | 0.6146 | -- | 2.43 | 46,943.05 | -124.63 | -161.38 | -289.30 | -449.76 | 11.08 | -79.79 | -202.80 | -495.77 | 0.8699 | -57.41 | 0.3901 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 717.97m | 487.00 | -- | 1.02 | -- | 7.88 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| National Research Corporation | 147.42m | 30.36m | 719.18m | 435.00 | 24.30 | 19.47 | 19.80 | 4.88 | 1.24 | 1.24 | 6.02 | 1.55 | 1.16 | -- | 11.53 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.55 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 725.50m | 50.00 | -- | 2.31 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 730.69m | 1.92k | 55.53 | 2.71 | 15.00 | 0.731 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Nuvation Bio Inc | 0.00 | -68.87m | 731.63m | 159.00 | -- | 1.09 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 731.90m | 140.00 | -- | 2.76 | -- | 19.66 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Stoke Therapeutics Inc | 7.85m | -108.53m | 733.07m | 110.00 | -- | 4.66 | -- | 93.44 | -2.42 | -2.42 | 0.1747 | 3.02 | 0.0322 | -- | 31.19 | 71,318.18 | -44.57 | -31.62 | -51.70 | -33.92 | -- | -- | -1,383.40 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Regenxbio Inc | 86.73m | -260.15m | 736.87m | 344.00 | -- | 1.88 | -- | 8.50 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| GH Research PLC | 0.00 | -35.59m | 746.08m | 49.00 | -- | 3.41 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 751.91m | 266.00 | -- | 29.58 | -- | 6.66 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 756.57m | 300.00 | -- | 2.11 | -- | 3.95 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 773.45m | 82.00 | -- | 2.61 | -- | 352.37 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Data as of May 28 2024. Currency figures normalised to SAGE Therapeutics Inc's reporting currency: US Dollar USD
62.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.87m | 9.76% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 5.60m | 9.32% |
| RTW Investments LPas of 31 Mar 2024 | 5.48m | 9.12% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 4.75m | 7.91% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.49m | 7.48% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 4.47m | 7.43% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 3.81m | 6.33% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.19m | 1.98% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.04m | 1.72% |
| Palo Alto Investors LPas of 31 Mar 2024 | 1.01m | 1.67% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
